Editas Medicine’s entry into the stock market with a $94.4 million initial public offering appears to be sparking positive signals for the company as well as the nascent gene-editing industry.… Read More
Editas Medicine filed the paperwork for an initial public offering today, marking a first for the growing number of private ventures that aim to take advantage of a powerful gene-editing… Read More